Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Andreas Busch

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

- PMLiVE

PMEA 2016 finalists announced

AbbVie, Bayer, Celgene and Novartis are up for the prestigious Company of the Year

Roche - Basel

Lucentis claims speedy FDA review for myopia complication

Roche’s drug achieved superior visual acuity gains compared to standard treatment in trials

Bayer symbol

Bayer and Merck take high-risk heart failure drug into phase III

Embarks on final study of vericiguat despite it not meeting objectives in phase II trial

- PMLiVE

NICE backs Bayer’s Eylea as first-line BRVO treatment

Recommends visual impairment therapy over current laser treatment

Shire Basingstoke

Shire gives up on Momenta-partnered Humira biosimilar

Will fund programme for another 12 months while divesting ongoing activities to Momenta

Shire Basingstoke

Shire launches dry eye drug Xiidra in US

Sparks rivalry with Allergan’s blockbuster Restasis as first new dry eye treatment in 13 years

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

- PMLiVE

Rare blood cancer therapy Oncaspar gets NICE green light

Baxalta’s acute lymphoblastic leukaemia treatment recommended for NHS use

Bayer symbol

Xarelto leads the charge at Bayer

Impressive sales for the oral anticoagulant bolsters weaker crop science and animal health performance

- PMLiVE

HIV prevention pill heads July CHMP recommendations

Gilead’s Truvada given positive opinion alongside Ipsen Pharma’s Cabometyx and Eisai’s Kisplyx

Shire Basingstoke

FDA finally approves Shire’s potential blockbuster Xiidra

Dry eye disease treatment wins US licence

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links